Stealth UK biotech in-licenses Lilly candidates in pursuit of 'inhibiting the inhibitor' in cardiovascular disease
Just last April, biotech incubator Cambridge Science spun out a tiny biotech to focus solely on cardiovascular disease. A year later, it has acquired two early-stage candidates developed in the forges of Eli Lilly’s R&D labs — and while the biotech won’t release any financial specifics yet, it’s barreling full-steam ahead to the clinic.
The biotech in question? A tiny UK-based startup called Kyttaro, with an office in Cambridge, MA. While founder and CEO Douglas Eby has been based out of Harvard for the last couple of years, Eby said that he and the incubator he founded decided that the UK would be a better place to start the company. The valuations of UK biotechs were more promising than in the US, he said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
